Organon (OGN) announced on Friday that its supplemental new drug application for Nexplanon has received approval from the US Food and Drug Administration, extending the use to up to five years from three years previously.

Nexplanon is indicated for use by women of reproductive potential to prevent pregnancy, according to the company.

There were no reported pregnancies and no new safety findings during the clinical study evaluating the safety and efficacy of extended use, Organon said.

Shares of the company were down 1.9% in recent Tuesday premarket activity.